Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine

• Main Authors: Marc Lallemant, Nicole Ngo-Giang-Huong, Gonzague Jourdain, Patrinee Traisaithit, Tim R. Cressey, Intira J. Collins, Tapnarong Jarupanich, Thammanoon Sukhumanant, Jullapong Achalapong, Prapan Sabsanong, Nantasak Chotivanich, Narong Winiyakul, Surabon Ariyadej, Annop Kanjanasing, Janyaporn Ratanakosol, Jittapol Hemvuttiphan, Karun Kengsakul, Wiroj Wannapira, Veerachai Sittipiyasakul, Witaya Pornkitprasarn, Prateung Liampongsabuddhi, Kenneth Mcintosh, Russell B. Van Dyke, Lisa M. Frenkel, Suporn Koetsawang, Sophie Le Coeur, Siripon Kanchana
• Format: Journal
• Published: 2018
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77749282888&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/51095
• Institution: Chiang Mai University

Background. Intrapartum single-dose nevirapine plus third trimester maternal and infant zidovudine are essential components of programs to prevent mother-to-child transmission of human immunodeficiency virus (HIV) in resource-limited settings. The persistence of nevirapine in the plasma for 3 weeks...